This technology is a therapeutic strategy to prevent brain damage and secondary disease in neonates with hypoxic-ischemic encephalopathy.
Neonatal hypoxic-ischemic encephalopathy (HIE) is a neurological disease that disrupts blood and oxygen supply to the brain. HIE can result in serious long-term consequences, including cerebral palsy, epilepsy, developmental delay, and cognitive impairment. To date, the only available treatment for HIE is therapeutic hypothermia, which is often ineffective, time- and resource-intensive, and can result in negative secondary side effects.
This therapy consists of stable omega-3 diglyceride emulsions that can be administered intravenously to newborns shortly after birth. The technology is rapid-acting, effective, and is shown to be well-tolerated with few side effects. Omega-3 diglyceride administration results in a strong increase in protective brain factors as well as a significant reduction of brain tissue damage. Overall, this technology provides a safe and effective alternative treatment to current therapeutic options for neonatal HIE.
This technology has been validated with in vitro cell lines and preclinical rodent models.
Richard Joseph Deckelbaum, M.D.
Patent Pending
IR CU21126
Licensing Contact: Sara Gusik